---
layout: default
title: Probenecid
description: "Probenecid çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 141
evidence_level: L4
indication_count: 3
---

# Probenecid

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Probenecidï¼šå¾ç—›é¢¨åˆ°è…æ€§ä½å°¿é…¸è¡€ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Probenecid å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Probenecid æ˜¯ä¸€ç¨®å°¿é…¸æ’æ³„ä¿ƒé€²åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼ç—›é¢¨å’Œç—›é¢¨æ€§é—œç¯€ç‚çš„æ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**è…æ€§ä½å°¿é…¸è¡€ç—‡ (Renal Hypouricemia)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç—›é¢¨ã€ç—›é¢¨æ€§é—œç¯€ç‚ã€å°¿é…¸æ’æ³„å¢é€² |
| é æ¸¬æ–°é©æ‡‰ç—‡ | obsolete hyperuricemia (disease)ã€hypouricemia, renalã€Lesch-Nyhan syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.73% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. hypouricemia, renal</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.73%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Probenecid æ˜¯ä¸€ç¨®ä¿ƒé€²å°¿é…¸æ’æ³„çš„è—¥ç‰©ï¼Œä¸»è¦ä½œç”¨æ–¼è…å°ç®¡ï¼ŒæŠ‘åˆ¶å°¿é…¸çš„å†å¸æ”¶ï¼Œå¾è€Œå¢åŠ å°¿é…¸æ’æ³„ã€‚åœ¨ç—›é¢¨æ‚£è€…ä¸­ï¼Œå®ƒè¢«ç”¨ä¾†é™ä½è¡€æ¸…å°¿é…¸æ°´å¹³ã€‚

ç„¶è€Œï¼Œå°æ–¼è…æ€§ä½å°¿é…¸è¡€ç—‡çš„æ‚£è€…ï¼Œä»–å€‘çš„å•é¡Œæ°å¥½ç›¸åâ€”â€”ä»–å€‘çš„è…è‡Ÿå·²ç¶“éåº¦æ’æ³„å°¿é…¸ï¼Œå°è‡´è¡€æ¸…å°¿é…¸éä½ã€‚é€™é€šå¸¸æ˜¯ç”±æ–¼ URAT1ï¼ˆå°¿é…¸è½‰é‹è›‹ç™½ï¼‰åŸºå› çªè®Šå°è‡´çš„éºå‚³æ€§ç–¾ç—…ã€‚

åœ¨é€™ç¨®æƒ…æ³ä¸‹ï¼Œprobenecid çš„è‡¨åºŠæ‡‰ç”¨ä¸»è¦æ˜¯ä½œç‚º**è¨ºæ–·å·¥å…·**è€Œéæ²»ç™‚è—¥ç‰©ã€‚é€šé probenecid è² è·è©¦é©—ï¼Œå¯ä»¥å¹«åŠ©é†«å¸«åˆ¤æ–·è…æ€§ä½å°¿é…¸è¡€ç—‡çš„äºå‹ï¼š
- æ­£å¸¸åæ‡‰ï¼šæç¤ºåˆ†æ³Œå¾Œå†å¸æ”¶ç¼ºé™·
- æ¸›å¼±åæ‡‰ï¼šæç¤ºåˆ†æ³Œå‰å†å¸æ”¶ç¼ºé™·

æ–‡ç»ä¸­çš„ç ”ç©¶ä¸»è¦æ¢è¨ probenecid åœ¨é€™äº›æ‚£è€…ä¸­çš„è—¥ç†å­¸åæ‡‰ç‰¹å¾µï¼Œè€Œéå…¶æ²»ç™‚æ•ˆæœã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [16678460](https://pubmed.ncbi.nlm.nih.gov/16678460/) | 2006 | Review | Mol Genet Metab | éºå‚³æ€§è…æ€§ä½å°¿é…¸è¡€ç—‡çš„å›é¡§ï¼Œprobenecid ç”¨æ–¼æ©Ÿè½‰ç ”ç©¶ |
| [14694169](https://pubmed.ncbi.nlm.nih.gov/14694169/) | 2004 | Journal Article | JASN | æ—¥æœ¬è…æ€§ä½å°¿é…¸è¡€ç—‡æ‚£è€…çš„ URAT1 åŸºå› èˆ‡ probenecid åæ‡‰åˆ†æ |
| [7771493](https://pubmed.ncbi.nlm.nih.gov/7771493/) | 1995 | Case Report | Am J Kidney Dis | è…æ€§ä½å°¿é…¸è¡€ç—‡å°è‡´é‹å‹•èª˜ç™¼æ€¥æ€§è…è¡°ç«­çš„é é˜² |
| [854144](https://pubmed.ncbi.nlm.nih.gov/854144/) | 1977 | Case Report | Nephron | å®¶æ—æ€§è…æ€§ä½å°¿é…¸è¡€ç—‡å° probenecid çš„æ¸›å¼±åæ‡‰ |
| [31650389](https://pubmed.ncbi.nlm.nih.gov/31650389/) | 2020 | Review | Clin Rheumatol | é¢¨æ¿•ç§‘é†«å¸«æ‡‰äº†è§£çš„ä½å°¿é…¸è¡€ç—‡çŸ¥è­˜ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. Lesch-Nyhan syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.39%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.39%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. hypoxanthine guanine phosphoribosyltransferase partial deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.37%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.37%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | æ™®æ¨‚å€å°¼è¥¿ç‰¹éŒ ç­‰ | éŒ åŠ‘ | ç—›é¢¨ã€ç—›é¢¨æ€§é—œç¯€ç‚ |

## å®‰å…¨æ€§è€ƒé‡

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**æ¶ˆåŒ–æ€§æ½°ç˜ (Peptic Ulcer)** ğŸŸ¡ Moderate
- The manufacturer states that probenecid should be used with caution in patients with a history of peptic ulcer.  Uricosuric agents can cause upper gastrointestinal irritation and aggravate or reactivate peptic ulcer.  However, these effects have prim...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Probenecid may not be effective in patients with chronic renal insufficiency, particularly when glomerular filtration rate is 30 mL/min or less.  Probenecid has been used in patients with some renal impairment but dosage requirements may be increased...

**Hematologic Diseases** ğŸŸ¢ Minor
- The manufacturer does not recommend the use of probenecid in patients with known blood dyscrasias.  Aplastic anemia, leukopenia, hemolytic anemia and other anemia have been reported infrequently during administration of probenecid.  Glucose-6-phospha...

**Dehydration** ğŸŸ¢ Minor
- Probenecid may promote lithiasis by increasing uric acid concentration in the renal tubules.  Adequate hydration is necessary during therapy.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the dev...

**Nephrolithiasis** ğŸŸ¢ Minor
- The use of probenecid is not recommended in patients with a history of uric acid nephrolithiasis or a urinary urate excretion greater than 750 mg/24 hr.  Probenecid may promote lithiasis by increasing uric acid concentration in the renal tubules.  Ad...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
Probenecid å°è…æ€§ä½å°¿é…¸è¡€ç—‡æ‚£è€…çš„ä½œç”¨ä¸»è¦æ˜¯ä½œç‚ºè¨ºæ–·å·¥å…·ï¼Œè€Œéæ²»ç™‚è—¥ç‰©ã€‚é€™äº›æ‚£è€…å·²ç¶“æœ‰éåº¦çš„å°¿é…¸æ’æ³„ï¼Œä½¿ç”¨ä¿ƒå°¿é…¸æ’æ³„åŠ‘å¯èƒ½æœƒé€²ä¸€æ­¥åŠ é‡ç—…æƒ…ã€‚æ–‡ç»ä¸­çš„ç ”ç©¶ä¸»è¦æ¢è¨è—¥ç†å­¸æ©Ÿè½‰ï¼Œè€Œéæ²»ç™‚æ•ˆæœã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ¾„æ¸…é æ¸¬ç›®çš„ï¼šæ˜¯ç”¨æ–¼è¨ºæ–·é‚„æ˜¯æ²»ç™‚
- è‹¥ç”¨æ–¼è¨ºæ–·ï¼Œéœ€ç¢ºç«‹æ¨™æº–åŒ–çš„è² è·è©¦é©—æ–¹æ¡ˆ
- è‹¥è€ƒæ…®ä»»ä½•æ²»ç™‚ç”¨é€”ï¼Œéœ€é€²è¡Œå®‰å…¨æ€§è©•ä¼°


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Aluminum Oxide]({{ "/drugs/aluminum_oxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Brodalumab]({{ "/drugs/brodalumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Pralatrexate]({{ "/drugs/pralatrexate/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Prednisolone Acetate]({{ "/drugs/prednisolone_acetate/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Vismodegib]({{ "/drugs/vismodegib/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Probenecidè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/probenecid/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_probenecid,
  title = {Probenecidè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/probenecid/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
